

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF SANBEXIN[®] (EDARAVONE AND DEXBORNEOL CONCENTRATED SOLUTION FOR INJECTION) INTO THE 2026 NATIONAL ESSENTIAL MEDICINES LIST

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on July 9, 2026, SANBEXIN[®] (Edaravone and Dexborneol Concentrated Solution for Injection), a Category 1 innovative drug independently developed by the Group for the treatment of acute ischemic stroke (“**AIS**”), has been officially included in the National Essential Medicines List (2026 Edition). According to the relevant management regulations for essential medicines, public medical institutions at all levels nationwide are required to equip and give priority to the use of medicines listed in the catalog. The inclusion is highly beneficial for the product to break through the limitations of Class Grade III Type A (3A) hospitals, accelerate market penetration into county-level and primary healthcare markets, and expand terminal prescription scenarios. Compounded with its existing medical insurance qualifications, this milestone will further enhance the accessibility of the medicine and solidify the Group’s competitive edge in the therapeutic field of acute stroke.

ABOUT SANBEXIN®

SANBEXIN® was approved for marketing in China in July 2020. SANBEXIN® has been included in the National Reimbursement Drug List (NRDL) since December 2020 and successfully renewed its inclusion in November 2024. Two large-scale Phase III clinical trials, namely TASTE (targeting the non-thrombectomy population and published in Stroke) and TASTE-2 (targeting the thrombectomy-combined population and published in The BMJ), demonstrated that Edaravone and Dexborneol alone or in combination with endovascular thrombectomy significantly improves the proportion of AIS patients achieving functional independence at Day 90, with a favorable safety profile. Meanwhile, SANBEXIN® is the only brain cell protectant with a Class IIa recommendation in the Guidelines for Clinical Management of Cerebrovascular Diseases in China (Second Edition) for improving clinical outcomes in AIS patients. As one of the standard treatment regimens for AIS, SANBEXIN® has benefited over 6 million AIS patients since its launch.

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company and the Group has established a “State Key Laboratory of Neurology and Oncology Drug Development”. The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “for patients, for life”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Executive Director

Hong Kong, July 9, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.